Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             105 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 O16 A regional prison cleared of hepatitis C in less than 12 months Russell, D.B.
3 S2 p. 6
 artikel
2 O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued Kwon, A.J.
3 S2 p. 5
 artikel
3 O28 Challenges ahead in primary care on the path to elimination Allard, N.
3 S2 p. 10
 artikel
4 O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study Alavi, M.
3 S2 p. 9
 artikel
5 O14 Community prescribing of hepatitis C treatment: a mentorship and capacity building model to increase treatment uptake by targeted populations Watkinson, S.
3 S2 p. 5-6
 artikel
6 O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study Grebely, J.
3 S2 p. 5
 artikel
7 O17 Eliminate Hepatitis C Partnership: clinical site scoping Wong, E.
3 S2 p. 7
 artikel
8 O27 Eliminating hepatitis C in the prisons: achievable? Lloyd, Andrew
3 S2 p. 10
 artikel
9 O30 Eliminating hepatitis C: the Cairns experience Russell, D.B.
3 S2 p. 11
 artikel
10 O31 Engaging Aboriginal and Torres Strait Islander communities McDonald, M.
3 S2 p. 11
 artikel
11 O32 Engaging community: the Cairns Hepatitis Action Team – paths to patient involvement Lewis, R.M.
3 S2 p. 11-12
 artikel
12 O3 HCV elimination program in Georgia: successes and challenges Butsashvili, M.
3 S2 p. 1-2
 artikel
13 O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study Dore, G.
3 S2 p. 8
 artikel
14 O29 Health promotion as a tool to engage marginalised populations Gorton, C.Z.
3 S2 p. 11
 artikel
15 O33 Health systems requirements for hepatitis elimination: are we ‘flying blind’ in our efforts Lazarus, Jeffrey V.
3 S2 p. 12
 artikel
16 O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective Doyle, J.S.
3 S2 p. 2
 artikel
17 O11 Hepatitis C: stigma indicators and patient reported outcome measures for DAA treatment Treloar, C.
3 S2 p. 4-5
 artikel
18 O1 Hepatitis C: the treatment landscape in 2017 Dore, Gregory J.
3 S2 p. 1
 artikel
19 O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study Hajarizadeh, B.
3 S2 p. 2-3
 artikel
20 O2 JoinJade: a culturally and linguistically tailored campaign to help end hepatitis B So, Samuel
3 S2 p. 1
 artikel
21 O25 ‘Many hands make light work’: upskilling the workforce for hepatitis C elimination Richmond, J.A.
3 S2 p. 9-10
 artikel
22 O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy Martinello, Marianne
3 S2 p. 3
 artikel
23 O20 Opportunities and challenges experienced when treating HCV in people who inject drugs (PWID) through a nurse-led outreach model Allardice, K.
3 S2 p. 8
 artikel
24 O8 Optimal liver cancer surveillance in the community: do recall and reminder systems hold the answer? Allard, N.L.
3 S2 p. 3-4
 artikel
25 O4 Outcomes of treatment for hepatitis C virus infection in the prison setting Papaluca, T.
3 S2 p. 2
 artikel
26 O26 Primary care-based viral hepatitis clinic in rural NSW: outcomes from the first 15 months of direct acting agents Balcomb, A.C.
3 S2 p. 10
 artikel
27 O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies Iversen, J.
3 S2 p. 4
 artikel
28 O15 Recommendations for hepatitis C virus testing among people who inject drugs in Australia Scott, N.
3 S2 p. 6
 artikel
29 O22 The International Coalition to Eliminate Hepatitis B Revill, P.
3 S2 p. 8-9
 artikel
30 O34 Towards elimination: the road forward from here Hellard, Margaret
3 S2 p. 12
 artikel
31 O19 Towards hepatitis C eradication in far North Queensland: a report on models of care and direct acting antiviral outcomes Lee, A.
3 S2 p. 7-8
 artikel
32 O18 Tracking in Arnhem Land: on the hunt for hepatitis B virus Hosking, K.A.
3 S2 p. 7
 artikel
33 O10 Treatment of Aboriginal and Torres Strait Islander clients with direct acting antivirals at the Kirketon Road Centre Gilliver, R.
3 S2 p. 4
 artikel
34 O24 Updating estimates describing the burden of hepatitis B in Australia. McCulloch, K.
3 S2 p. 9
 artikel
35 P50 Acceptability of hepatitis C treatment in community settings: qualitative part of a mixed method systematic review Pourmarzi, D.
3 S2 p. 29
 artikel
36 P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people Bajis, S.
3 S2 p. 13-14
 artikel
37 P51 Advanced liver disease nurse education program in NSW Pritchard-Jones, J.
3 S2 p. 29-30
 artikel
38 P41 Advancing the development of community-based models to access marginalised populations for hepatitis C treatment incorporating assessment, outreach and case management Murray, D.
3 S2 p. 26
 artikel
39 P21 An ehealth model of care for community hepatitis C management: the HealthElink project Haridy, J.
3 S2 p. 19-20
 artikel
40 P2 An immunochromatographic test for measurement of alanine aminotransferase (ALT) at point-of-care Anderson, D.
3 S2 p. 13
 artikel
41 P19 An innovative way to increase ongoing care for Chinese patients living with chronic hepatitis B Zhihong, G.
3 S2 p. 19
 artikel
42 P37 An integrated approach to viral hepatitis management in the community: tackling hepatitis B and C using a model of shared care McKee, K.
3 S2 p. 24-25
 artikel
43 P47 A pilot study to inform, test and treat people from non-english speaking backgrounds living with chronic hepatitis in Western Australia Pattni, I.
3 S2 p. 27-28
 artikel
44 P66 A year of living safely: 12 months of DAA treatment in Canberra's prison system Wenke, J.
3 S2 p. 34-35
 artikel
45 P52 ‘Behind closed doors, no one sees, no one knows’: stigma and treatment as prevention in prison Rance, J.
3 S2 p. 30
 artikel
46 P13 Call: community assessment and liver liaison, a liver clinic provided to homeless men in their community Dowdell, L.
3 S2 p. 16-17
 artikel
47 P55 Client acceptability and feasibility of expanded access to direct acting antiviral therapy for hepatitis at the Kirketon Road Centre Chronister, K.J.
3 S2 p. 31
 artikel
48 P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir Reau, N.
3 S2 p. 34
 artikel
49 P39 Does the cure for hepatitis C start at moment of diagnosis? An analysis of Canadian women's experiences Mitchell, S.
3 S2 p. 25
 artikel
50 P58 Education of general practitioners (GPs) regarding hepatitis C (HCV): the use of plan, do, study, act (PDSA) cycles Scarborough, J.
3 S2 p. 31-32
 artikel
51 P70 Elimination of hepatitis C in a prison setting Lobo, C.
3 S2 p. 36
 artikel
52 P15 Engagement of the notorious mongrel mob and their knowledge of hepatitis C Fraser, M.
3 S2 p. 17
 artikel
53 P34 Expanding access to treatment for patients with hepatitis C through the use of the remote access request form Nazareth, S.
3 S2 p. 23-24
 artikel
54 P11 Far North Queensland aboriginal and Torres Strait Islander hepatitis B project Curran, G.
3 S2 p. 16
 artikel
55 P43 FIB-4 is superior to APRI and identifies HCV patients with less significant fibrosis who could be managed in primary care O’Beirne, J.
3 S2 p. 26
 artikel
56 P45 Frequency of HCV resistance associated substitutions at baseline and relapse O’Keefe, J.
3 S2 p. 27
 artikel
57 P26 HealthPathways Melbourne: assisting general practitioners and practice nurses to provide optimal care for patients with hepatitis C Janover, O.
3 S2 p. 21
 artikel
58 P27 Hepatitis B outreach to people who inject drugs (PWID) Kanaef, L.
3 S2 p. 21
 artikel
59 P69 Hepatitis B patient management system, Far North Queensland Aboriginal and Torres Strait Islander hepatitis B project Wilson, R.
3 S2 p. 35-36
 artikel
60 P1 Hepatitis C CALD community outreach Abdelsalam, D.
3 S2 p. 13
 artikel
61 P53 Hepatitis C diagnostic testing trends in Victoria, 2010–2015 Rawson, S.L.
3 S2 p. 30
 artikel
62 P42 Hepatitis C treatment in a community needle and syringe program as a method of engagement for injecting drug users Myers, L.
3 S2 p. 26
 artikel
63 P38 Hepatitis NSW's specialised counselling service: professional support for people undertaking DAA treatment for viral hepatitis C Pesa, L.
3 S2 p. 25
 artikel
64 P68 Hep Connect: delivering one-to-one telephone support to people undergoing HCV treatment by people who have treatment experience Wilkinson, S.
3 S2 p. 35
 artikel
65 P71 High hepatitis C cure rate in a general practice cohort Baker, D.
3 S2 p. 36
 artikel
66 P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis Puoti, Massimo
3 S2 p. 33
 artikel
67 P48 Implementing an elimination program for hepatitis C: a partnership approach from Victoria Pedrana, A.
3 S2 p. 28
 artikel
68 P40 Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland injectors’ health network Morris, L.
3 S2 p. 25-26
 artikel
69 P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study Cunningham, E.
3 S2 p. 15-16
 artikel
70 P25 Integration of hepatitis C assessment and treatment in a unique residential drug and alcohol treatment facility for women Boyd, F.
3 S2 p. 21
 artikel
71 P63 Knowledge and practices of chronic hepatitis B virus testing by general practitioners in Victoria, 2014–2015 Gemert, C.
3 S2 p. 33-34
 artikel
72 P32 Laws prohibiting peer distribution of injecting equipment in Australia Lancaster, K.
3 S2 p. 23
 artikel
73 P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure Poordad, Fred
3 S2 p. 28-29
 artikel
74 P44 Maximising access to hepatitis C (HCV) treatment: the Sunshine Coast experience O’Beirne, J.
3 S2 p. 27
 artikel
75 P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia Hajarizadeh, B.
3 S2 p. 19
 artikel
76 P22 ‘No closed door’ to HCV treatment in the era of fully funded DAAs: access to a peer navigator is essential Harrod, M.E.
3 S2 p. 20
 artikel
77 P7 No wrong door: do current referral pathways capture those at risk of onward HCV transmission? Bartlett, G.
3 S2 p. 15
 artikel
78 P65 Nurse-led hepatitis C treatment models in drug and alcohol services can support, treatment uptake, healthcare engagement and community prescribing Watkinson, S.
3 S2 p. 34
 artikel
79 P56 Opportunities for hepatitis organisations to compliment needle syringe programs for people who inject drugs by providing hepatitis C treatments Rowell, S.
3 S2 p. 31
 artikel
80 P36 Outcomes of general practitioner prescription of direct acting antiviral therapy utilising a remote consultation referral pathway in Western Victoria Wade, A.J.
3 S2 p. 24
 artikel
81 P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015 Bartlett, S.R.
3 S2 p. 14-15
 artikel
82 P5 Primary care-based viral hepatitis clinic in rural NSW: outcomes from the first 15 months of direct acting agents Balcomb, A.C.
3 S2 p. 14
 artikel
83 P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs Kavanagh, R.
3 S2 p. 22
 artikel
84 P59 Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade Scott, N.
3 S2 p. 32
 artikel
85 P12 Revitalising hepatitis B health promotion responses in Western Sydney: exploring new opportunities Devkota, A.
3 S2 p. 16
 artikel
86 P30 Scaling up or holding back? Contemplating treatment as prevention in the prison setting within Australia's current policy frameworks Lafferty, L.
3 S2 p. 22
 artikel
87 P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies Roberts, Stuart K.
3 S2 p. 17-18
 artikel
88 P14 Stigma and discrimination: an exploration of need and potential responses in Victoria, Australia Fitzpatrick, K.
3 S2 p. 17
 artikel
89 P67 Strategies supporting and increasing hepatitis C testing and treatment for people in NSW prisons Wilkinson, S.
3 S2 p. 35
 artikel
90 P23 Strategies towards the elimination of viral hepatitis in Queensland Haynes, K.
3 S2 p. 20
 artikel
91 P3 Successful treatment of hepatitis C among homeless and socially marginalised clients in primary care Andric, N.
3 S2 p. 13
 artikel
92 P60 Supporting hepatitis C treatment uptake by primary care providers: a successful model Sheils, S.
3 S2 p. 32
 artikel
93 P57 Taking hepatitis C issues to the homes of Arabic communities in NSW Sabri, W.
3 S2 p. 31
 artikel
94 P61 The accidental hepatitis C virus nurse: supporting HCV community treatment for people living with HIV and a mental illness Smith, M.
3 S2 p. 32-33
 artikel
95 P17 The impact of hepatitis C-related uncertainty on self-reported stress in people who inject drugs living with hepatitis C Goutzamanis, S.
3 S2 p. 18
 artikel
96 P33 The living well program: bringing hepatitis C treatment to marginalised people in residential rehabilitation centres Leadbeatter, K.
3 S2 p. 23
 artikel
97 P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT) Keats, J.
3 S2 p. 22
 artikel
98 P18 Treating the mob: providing hepatitis C treatment in an aboriginal community controlled health service is a successful model of care Hanley, B.
3 S2 p. 18-19
 artikel
99 P35 Treatment access for hepatitis C across Australia: mapping need and capacity MacLachlan, J.H.
3 S2 p. 24
 artikel
100 P54 Treatment adherence among people who inject drugs taking directly observed direct acting antiviral therapy at Kirketon Road Centre Chronister, K.J.
3 S2 p. 30
 artikel
101 P31 Treatment as prevention in the prison setting: prisoners’ perspectives Lafferty, L.
3 S2 p. 22-23
 artikel
102 P8 Using ‘teach-back’ with clients who live with chronic hepatitis B: does it improve understanding? Bennett, G.
3 S2 p. 15
 artikel
103 P24 What GP prescribers need to treat hepatitis C: results of an online survey Baker, D.
3 S2 p. 20
 artikel
104 P46 Yes I want to be tested: what next? Warning! Another obstacle course soon to begin … experiences of the community and bilingual workers Pattni, I.
3 S2 p. 27
 artikel
105 P9 Youth at risk: increasing youth workers’ knowledge and confidence to talk with young people about hep C and injecting Brown, T.
3 S2 p. 15
 artikel
                             105 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland